Insights on 21 Years of HBV Surveillance in Blood Donors in France

• Published in: Viruses Vol. 14; no. 11; p. 2507
• Main Authors: Cappy, Pierre, Boizeau, Laure, Candotti, Daniel, Le Cam, Sophie, Martinaud, Christophe, Pillonel, Josiane, Tribout, Martin, Maugard, Claude, Relave, Josiane, Richard, Pascale, Morel, Pascal, Laperche, Syria
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 12-11-2022; MDPI
• Subjects: acute HBV infection; Antibodies; Antigens; Blood & organ donations; blood donations; Blood Donors; Deoxyribonucleic acid; DNA; DNA, Viral - genetics; Epidemiology; Forecasts and trends; Genotypes; HBV; Hepatitis B; Hepatitis B - diagnosis; Hepatitis B Antibodies; Hepatitis B surface antigen; Hepatitis B Surface Antigens; Hepatitis B virus - genetics; Humans; Infections; Life Sciences; Methods; NAT; occult B infection; Pathogens; Plasma; Polymerase chain reaction; Population; Risk factors; Sentinel health events; Statistics; Surveillance; France; Sub-Saharan Africa; NAT; acute HBV infection; blood donations; HBV; occult B infection
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v14112507

Hepatitis B virus (HBV) infection is the most frequent viral infection found in blood donors (BDs) in France. We analyzed the epidemiological and sero-molecular data on HBV infection gathered over the past two decades by the French haemovigilance surveillance network, blood screening laboratories, and the national reference center for transfusion infectious risks (NRC). Between 2000 and 2020, 6149 of the 58,160,984 donations (1.06/10,000) tested HBV positive, 98% of them from first-time blood donors (FTBDs). In addition, 2212 (0.0071%) of the 30,977,753 donations screened for HBV DNA tested DNA positive, of which 25 (1.1%) were positive only for this marker. HBV prevalence decreased by 2.8-fold and the residual risk for transfusion-transmitted HBV infection decreased 13-fold and was divided by 13. The major risk factor for HBV infection was the origin of donors (endemic country, 66.5%), followed by parenteral exposure (10.7%). In the whole HBV-positive BD population, genotype D was predominant (41.8%), followed by genotypes A (26.2%) and E (20.4%), reflecting the geographical origin of donors. The low and decreasing prevalence and incidence of HBV infection in French BDs, coupled with a screening strategy using three HBV markers (HBsAg, anti-HBc and DNA), ensures a high level of blood safety, further reinforced by the implementation of pathogen-reduction measures.